Datum | Källa | Rubrik | Typ | Alternativ |
---|---|---|---|---|
2023-06-02 | Genovis | Genovis AB: Genovis launch Innovative IgM-Specific Protease with Wide-Ranging Applications in Life Science Markets | Pressreleaser | Ladda ner | Visa Stäng |
|
||||
2023-06-02 | Genovis | Genovis AB: Genovis lanserar unikt IgM-specifikt enzym med breda tillämpningar inom Life Science-marknaden | Pressreleaser | Ladda ner | Visa Stäng |
|
||||
2023-05-17 | Redeye | Redeye: Genovis Q1 2023 - Strongest report to date | Pressreleaser | Ladda ner | Visa Stäng |
|
||||
2023-05-16 | Genovis | Communiqué from Genovis AB (publ) Annual General Meeting May 16, 2023 | Pressreleaser | Ladda ner | Visa Stäng |
|
||||
2023-05-16 | Genovis | Kommuniké från Årsstämman i Genovis AB (publ) den 16 maj 2023 | Pressreleaser | Ladda ner | Visa Stäng |
|
||||
2023-05-16 | Genovis | Genovis AB: Interim Report January-March 2023 | Rapporter | Ladda ner | Visa Stäng |
|
||||
2023-05-16 | Genovis | Genovis AB: Kvartalsrapport januari-mars 2023 | Rapporter | Ladda ner | Visa Stäng |
|
||||
2023-05-03 | Genovis | Genovis AB: Genovis and ArcticZymes Technologies enter into a collaboration agreement to accelerate growth in China | Pressreleaser | Ladda ner | Visa Stäng |
|
||||
2023-05-03 | Genovis | Genovis AB: Genovis och ArcticZymes Technologies ingår samarbetsavtal för att accelerera tillväxt på den kinesiska marknaden | Pressreleaser | Ladda ner | Visa Stäng |
|
||||
2023-04-25 | Genovis | Genovis AB: Genovis acquires IP Rights to novel enzymes for applications within genomics | Pressreleaser | Ladda ner | Visa Stäng |
|
||||
2023-04-25 | Genovis | Genovis AB: Genovis förvärvar patenträttigheter till nytt enzym inom genomics | Pressreleaser | Ladda ner | Visa Stäng |
|
||||
2023-04-25 | Genovis | Genovis AB: Genovis årsredovisning 2022 publicerad | Pressreleaser | Ladda ner | Visa Stäng |
|
||||
2023-04-25 | Genovis | Genovis AB: Genovis Annual Report 2022 published | Pressreleaser | Ladda ner | Visa Stäng |
|
||||
2023-04-11 | Genovis | Genovis AB: NOTICE CONVENING THE 2023 ANNUAL GENERAL MEETING | Pressreleaser | Ladda ner | Visa Stäng |
|
||||
2023-04-11 | Genovis | Genovis AB: KALLELSE TILL ÅRSSTÄMMA 2023 | Pressreleaser | Ladda ner | Visa Stäng |
|
||||
2023-02-16 | Redeye | Redeye: Genovis Q4 2022 - A First Sublicensing of Xork | Pressreleaser | Ladda ner | Visa Stäng |
|
||||
2023-02-15 | Genovis | Genovis AB: Year-end Report January-December 2022 | Rapporter | Ladda ner | Visa Stäng |
|
||||
2023-02-15 | Genovis | Genovis AB: Bokslutskommuniké januari-december 2022 | Rapporter | Ladda ner | Visa Stäng |
|
||||
2023-01-09 | Genovis | Genovis AB: Genovis erhåller direkt 4 MUSD efter att Selecta Biosciences sub-licensierat Xork™-enzymet till Astellas Pharma | Pressreleaser | Ladda ner | Visa Stäng |
|
||||
2023-01-09 | Genovis | Genovis AB: Genovis to receive 4 MUSD upfront after Selecta Biosciences sublicensed Xork™ enzyme to Astellas Pharma | Pressreleaser | Ladda ner | Visa Stäng |
Pressreleaser |
Genovis AB: Genovis to receive 4 MUSD upfront after Selecta Biosciences sublicensed Xork™ enzyme to Astellas PharmaAs part of the licensing agreement entered between Genovis AB and Selecta Biosciences Inc. in 2021, Genovis will receive 4 MUSD upfront following the sublicensing of the Xork enzyme from Selecta Bioscience Inc. to Astellas Pharma Inc. Genovis is eligible to receive additional sublicense revenues up to 135 MUSD from development and commercialization plus royalties on sales where Xork and AT845 are used for treatment of Pompe Disease. ”The license agreement between Selecta Biosciences and Astellas Pharma validates both the value of the Xork enzyme as a potential pretreatment strategy for gene therapy and the partnership between Genovis and Selecta Bioscience. In our partnership with Selecta Biosciences, we will continue to target additional indications for Xork within the gene therapy field”, says Fredrik Olsson, CEO Genovis. This disclosure contains information that Genovis AB is obliged to make public pursuant to the EU Market Abuse Regulation (EU nr 596/2014). The information was submitted for publication, through the agency of the contact person, on 09-01-2023 13:58 CET. |
||||
2022-12-12 | Redeye | Redeye: Genovis - Bull Story, Fair Price | Analyser | Ladda ner | Visa Stäng |
|
||||
2022-11-15 | Genovis | Genovis AB: Interim Report January-September 2022 | Rapporter | Ladda ner | Visa Stäng |
|
||||
2022-11-15 | Genovis | Genovis AB: Delårsrapport januari-september 2022 | Rapporter | Ladda ner | Visa Stäng |
|